Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878300 | 0.82 | F10 (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL4877155 | 0.80 | F10 (0.40) | SMN1; SMN2 | |
| SCHEMBL4877161 | 0.69 | CHEK1 (0.31) | — | |
| SCHEMBL4884124 | 0.68 | DGAT1 (0.31) | — | |
| SCHEMBL4882648 | 0.67 | F10 (0.43) | KDM4EMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL14066578 | 0.67 | F10 (0.43) | KDM4EMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4876089 | 0.66 | F10 (0.37) | SMN1; SMN2 | |
| SCHEMBL4710501 | 0.65 | RAB9A (0.42) | KDM4EMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4879114 | 0.65 | F2 (0.38) | — | |
| SCHEMBL4881623 | 0.65 | SMN1; SMN2 (0.38) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | PTPN1 2894/4885KDM4E 3856/4885MEN1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.